26820-63-3 | 5-Nitro-2-pyrrolidinopyridine

123-75-1    2530-26-9    26820-63-3 

[1]Gulevskaya,AnnaV.;Maes,BertU.W.;Meyers,Caroline;Herrebout,WouterA.;VanDerVeken,BenjaminJ.[EuropeanJournalofOrganicChemistry,2006,#23,p.5305-5314]

[2]Locationinpatent:experimentalpartVerbeeck,Stefan;Herrebout,WouterA.;Gulevskaya,AnnaV.;VanDerVeken,BenjaminJ.;Maes,BertU.W.[JournalofOrganicChemistry,2010,vol.75,#15,p.5126-5133]

[3]Locationinpatent:experimentalpartVerbeeck,Stefan;Herrebout,WouterA.;Gulevskaya,AnnaV.;VanDerVeken,BenjaminJ.;Maes,BertU.W.[JournalofOrganicChemistry,2010,vol.75,#15,p.5126-5133]

123-75-1    4548-45-2    26820-63-3 

[1]Isanbor,Chukwuemeka;Emokpae,ThomasA.[InternationalJournalofChemicalKinetics,2008,vol.40,#3,p.125-135]

[2]CurrentPatentAssignee:NEUROPORETHERAPIES-WO2020/198368,2020,A1Locationinpatent:Paragraph0425

[3]Oslob,JohanD.;Johnson,RussellJ.;Cai,Haiying;Feng,ShirleyQ.;Hu,Lily;Kosaka,Yuko;Lai,Julie;Sivaraja,Mohanram;Tep,Samnang;Yang,Hanbiao;Zaharia,CristianaA.;Evanchik,MarcJ.;McDowell,RobertS.[ACSMedicinalChemistryLetters,2013,vol.4,#1,p.113-117]

[4]McPhillie,MartinJ.;Trowbridge,Rachel;Mariner,KatherineR.;O'Neill,AlexJ.;Johnson,A.Peter;Chopra,Ian;Fishwick,ColinW.G.[ACSMedicinalChemistryLetters,2011,vol.2,#10,p.729-734]

[5]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-WO2013/13817,2013,A1Locationinpatent:Page/Pagecolumn134

[6]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-WO2013/13815,2013,A1Locationinpatent:Page/Pagecolumn190

[7]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-US2013/29961,2013,A1Locationinpatent:Paragraph0784

[8]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-US2013/29962,2013,A1Locationinpatent:Paragraph0971

[9]CurrentPatentAssignee:ABBVIEINC-US2010/317568,2010,A1

[10]Walsh,Katie;Sneddon,HelenF.;Moody,ChristopherJ.[ChemSusChem,2013,vol.6,#8,p.1455-1460]

[11]Guo,Ming;Zuo,Daiying;Zhang,Junlong;Xing,Lingyun;Gou,Wenfeng;Jiang,Feng;Jiang,Nan;Zhang,Dajun;Zhai,Xin[EuropeanJournalofMedicinalChemistry,2018,vol.158,p.322-333]

[12]CurrentPatentAssignee:PFIZERINC-US2003/36652,2003,A1

[13]Isanbor,Chukwuemeka;Emokpae,ThomasA.[InternationalJournalofChemicalKinetics,2008,vol.40,#3,p.125-135]

[14]Crampton,MichaelR.;Emokpae,ThomasA.;Isanbor,Chukwuemeka[EuropeanJournalofOrganicChemistry,2007,#8,p.1378-1383]

[15]CurrentPatentAssignee:PFIZERINC-US6407120,2002,B1Locationinpatent:Pagecolumn33

[16]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-US2012/108583,2012,A1Locationinpatent:Page/Pagecolumn29

[17]CurrentPatentAssignee:MONTEROSATHERAPEUTICSAG-WO2022/152822,2022,A1Locationinpatent:Page/Pagecolumn181;264

[18]CurrentPatentAssignee:MONTEROSATHERAPEUTICSAG-WO2022/152822,2022,A1Locationinpatent:Page/Pagecolumn181;264

26820-63-3   

6-(pyrrolidin-1-yl)pyridin-3-amine 

[1]Oslob,JohanD.;Johnson,RussellJ.;Cai,Haiying;Feng,ShirleyQ.;Hu,Lily;Kosaka,Yuko;Lai,Julie;Sivaraja,Mohanram;Tep,Samnang;Yang,Hanbiao;Zaharia,CristianaA.;Evanchik,MarcJ.;McDowell,RobertS.[ACSMedicinalChemistryLetters,2013,vol.4,#1,p.113-117]

[2]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-WO2013/13817,2013,A1Locationinpatent:Page/Pagecolumn134

[3]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-WO2013/13815,2013,A1Locationinpatent:Page/Pagecolumn190

[4]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-US2013/29961,2013,A1Locationinpatent:Paragraph0785

[5]CurrentPatentAssignee:GruenenthalPharmaGmbH&Co.Kommanditgesellschaft-US2013/29962,2013,A1Locationinpatent:Paragraph0972

[6]Guo,Ming;Zuo,Daiying;Zhang,Junlong;Xing,Lingyun;Gou,Wenfeng;Jiang,Feng;Jiang,Nan;Zhang,Dajun;Zhai,Xin[EuropeanJournalofMedicinalChemistry,2018,vol.158,p.322-333]

[7]CurrentPatentAssignee:PFIZERINC-US6407120,2002,B1Locationinpatent:Pagecolumn33

[8]Locationinpatent:schemeortableAmato,George;Roeloffs,Rosemarie;Rigdon,GregC.;Antonio,Brett;Mersch,Theresa;McNaughton-Smith,Grant;Wickenden,AlanD.;Fritch,Paul;Suto,MarkJ.[ACSMedicinalChemistryLetters,2011,vol.2,#6,p.481-484]

[9]McPhillie,MartinJ.;Trowbridge,Rachel;Mariner,KatherineR.;O'Neill,AlexJ.;Johnson,A.Peter;Chopra,Ian;Fishwick,ColinW.G.[ACSMedicinalChemistryLetters,2011,vol.2,#10,p.729-734]

[10]CurrentPatentAssignee:GLENMARKPHARMACEUTICALSLTD-US2012/108583,2012,A1Locationinpatent:Page/Pagecolumn29

[11]CurrentPatentAssignee:MONTEROSATHERAPEUTICSAG-WO2022/152822,2022,A1Locationinpatent:Page/Pagecolumn181;264

[12]CurrentPatentAssignee:MONTEROSATHERAPEUTICSAG-WO2022/152822,2022,A1Locationinpatent:Page/Pagecolumn181;264

7440-44-0    26820-63-3   

6-(pyrrolidin-1-yl)pyridin-3-amine 

[1]CurrentPatentAssignee:PFIZERINC-US2003/36652,2003,A1